Childhood Cancer Survivors Have Increased Risk for CKD, Hypertension
By Elana Gotkine HealthDay Reporter
THURSDAY, May 22, 2025 -- Childhood cancer survivors (CCS) have an increased risk for chronic kidney disease (CKD) and hypertension, according to a study published online May 19 in JAMA Network Open.
Asaf Lebel, M.D., from The Hospital for Sick Children in Toronto, and colleagues examined the association of childhood cancer treatment with post-cancer-therapy CKD or hypertension in a population-based matched cohort study of children treated for cancer. The CCS (exposed cohort) included children surviving cancer who were matched to a hospitalization cohort (children who were hospitalized) and a general pediatric population (GP) cohort.
Data were included for 10,182 CCS matched to 40,728 hospitalization cohort patients and 8,849 CCS matched to 35,307 GP cohort participants. Leukemia, central nervous system neoplasms, and lymphoma were the most frequent cancer types (29.0, 20.9, and 15.5 percent, respectively). The researchers found that the cumulative incidence of CKD or hypertension was 20.85 versus 16.47 percent in the CCS versus hospitalization cohorts during observation and 19.24 versus 8.05 percent in the CCS versus GP cohorts. Compared with the hospitalization and GP cohorts, CCS had increased risk for CKD and hypertension (adjusted hazard ratios, 2.00 and 4.71, respectively).
"Increasing specificity and action-oriented guidance of CCS surveillance guidelines, by collaboration of kidney and cancer stakeholder organizations, may help mitigate CKD and hypertension-associated morbidity and mortality," the authors write.
One author disclosed ties to Amgen and Janssen.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 -- For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care...
Empagliflozin Has Kidney Protective Effects in Acute Myocardial Infarction
THURSDAY, June 26, 2025 -- Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial...
Telehealth Intervention Beneficial for Seniors With Metastatic Cancer
WEDNESDAY, June 25, 2025 -- The telehealth-administered Geriatric Assessment–Guided Intervention (GAIN-S) improves physical function, mood, quality of life, and prognostic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.